Abstract
Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Current Topics in Medicinal Chemistry
Title: Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity
Volume: 11 Issue: 21
Author(s): Chee Fei Chin, Daniel Yuan Qiang Wong, Ramasamy Jothibasu and Wee Han Ang
Affiliation:
Keywords: Cisplatin, anticancer prodrugs, platinum drugs, activation by reduction, targeted delivery, targeting and killing cancer cells, platinum(IV) constructs, electrochemical characteristics and, structural attributes of platinum(IV) complexes, Anticancer platinum(IV) prodrugs, targeted chemotherapeutic agents, potent antitumour agent, colorectal, non-small cell lung and genitourinary cancers
Abstract: Over the past four decades, the search for improved platinum drugs based on the classical platinum(II)- diam(m)ine pharmacophore has yielded only a handful of successful candidates. New methodologies centred on platinum( IV) complexes, with better stability and expanded coordination spheres, offer the possibility of overcoming limitations inherent to platinum(II) drugs. In this review, novel strategies of targeting and killing cancer cells using platinum( IV) constructs are discussed. These approaches exploit the unique electrochemical characteristics and structural attributes of platinum(IV) complexes as a means of developing anticancer prodrugs that can target and selectively destroy cancer cells. Anticancer platinum(IV) prodrugs represent promising new strategies as targeted chemotherapeutic agents in the ongoing battle against cancer.
Export Options
About this article
Cite this article as:
Fei Chin Chee, Yuan Qiang Wong Daniel, Jothibasu Ramasamy and Han Ang Wee, Anticancer Platinum (IV) Prodrugs with Novel Modes of Activity, Current Topics in Medicinal Chemistry 2011; 11 (21) . https://dx.doi.org/10.2174/156802611798040778
DOI https://dx.doi.org/10.2174/156802611798040778 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Surfactant Protein (SP)-A and SP-D as Antimicrobial and Immunotherapeutic Agents
Recent Patents on Anti-Infective Drug Discovery Predictive Biomarkers and Novel Targets in the Treatment of Metastatic Renal Cell Carcinoma
Current Medicinal Chemistry Neonatal Fc Receptor and its Role in the Absorption, Distribution, Metabolism and Excretion of Immunoglobulin G-Based Biotherapeutics
Current Drug Metabolism Gastrointestinal Stromal Tumors: A Paradigm for Therapeutic Options in Solid Organ Tumors
Mini-Reviews in Medicinal Chemistry Immunotherapy for Myeloproliferative Neoplasms (MPN)
Current Cancer Drug Targets Smell and Taste Disorders Resulting from Cancer and Chemotherapy
Current Pharmaceutical Design The Epidemiological, Mechanistic and Potential Clinical Role of Androgen Receptor (AR) in Urothelial Carcinoma
Current Drug Targets Recombinant Secretory Immunoglobulin A in Passive Immunotherapy: Linking Immunology and Biotechnology
Current Pharmaceutical Biotechnology Inhaled Dry Powder Formulations for Treating Tuberculosis
Current Drug Delivery Oncotargets in Different Renal Cancer Subtypes
Current Drug Targets Recent Patents Regarding Essential Oils and the Significance of their Constituents in Human Health and Treatment
Recent Patents on Anti-Infective Drug Discovery The Role of Capecitabine in the Management of Tumors of the Digestive System
Reviews on Recent Clinical Trials Tachykinins and their Receptors in Human Malignancies
Current Drug Targets <i>Nigella sativa</i> – A Functional Spice From A Pharaoh’s Tomb to Modern Healthcare
The Natural Products Journal The Potential of Flavonoids and Tannins from Medicinal Plants as Anticancer Agents
Anti-Cancer Agents in Medicinal Chemistry Nephrotonic and Nephroprotective Medicinal Herbs in Traditional Persian Medicine: Review and Assessment of Scientific Evidence
Current Traditional Medicine Cytotoxic Compounds in the Treatment of Castration-Resistant Prostate Cancer
Anti-Cancer Agents in Medicinal Chemistry Obesity: The Metabolic Disease, Advances on Drug Discovery and Natural Product Research
Current Topics in Medicinal Chemistry Perinatal Management of Fetal Tumors
Current Pediatric Reviews Emerging Targeted Therapies in Metastatic Renal Cell Carcinoma
Current Clinical Pharmacology